董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert P. Roche | 男 | Director | 63 | 10.94万美元 | 未持股 | 2019-03-13 |
| Craig A. Tooman | 男 | President, Chief Executive Officer and Director | 53 | 95.03万美元 | 未持股 | 2019-03-13 |
| Merilee Raines | 女 | Director | 63 | 10.69万美元 | 未持股 | 2019-03-13 |
| Craig A. Barbarosh | 男 | Director | 51 | 未披露 | 未持股 | 2019-03-13 |
| Irvine O. Hockaday, Jr. | 男 | Director | 82 | 10.29万美元 | 未持股 | 2019-03-13 |
| Lowell W. Robinson | 男 | Director | 70 | 未披露 | 未持股 | 2019-03-13 |
| John Vander Vort | 男 | Director | 54 | 10.69万美元 | 未持股 | 2019-03-13 |
| Laura Brege | 女 | Director | 61 | 11.44万美元 | 未持股 | 2019-03-13 |
| Wendy L. Yarno | 女 | Chairperson of the Board of Directors | 64 | 12.94万美元 | 未持股 | 2019-03-13 |
| David L. Brinkley | 男 | Director | 61 | 11.19万美元 | 未持股 | 2019-03-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Craig A. Tooman | 男 | President, Chief Executive Officer and Director | 53 | 95.03万美元 | 未持股 | 2019-03-13 |
| Rhonda L. Hellums | 女 | Chief Financial Officer and Treasurer | 47 | 未披露 | 未持股 | 2019-03-13 |
| Chris Ready | 男 | Vice President of Sales and Marketing | 45 | 未披露 | 未持股 | 2019-03-13 |
| John C. Ayres | 男 | Vice President - Corporate Development and Administration, General Counsel and Secretary | 40 | 未披露 | 未持股 | 2019-03-13 |
| Ernst Heinen | 男 | Chief Development Officer | 56 | 80.19万美元 | 未持股 | 2019-03-13 |
董事简历
中英对照 | 中文 | 英文- Robert P. Roche
-
Robert P. Roche，2014年6月起担任本董事会成员。是一家为医药和医疗行业提供指导的咨询公司- Robert Roche Associates, LLC的创始成员；于2010年2月从生物医药公司Cephalon, Inc.退休后，创立了该公司。于1995年1月加入Cephalon并担任销售和市场营销副总裁；2005年被任命为Cephalon全球医药业务执行副总裁。加入Cephalon前，曾在SmithKline Beecham的中枢神经系统和胃肠道产品业务部担任董事，副总裁，负责全球战略产品发展。还曾在Philippines的SmithKline担任医药业务总经理。此前，曾在加拿大和西班牙担任高级市场营销职位，曾在拉丁美洲SmithKline担任产品规划职位。于1982年在SmithKline担任美国医药销售代表开始他的医药职业生涯。从2013年7月起，在一家专业医药上市公司- Antares Pharma, Inc.担任董事；目前是该公司管理和提名委员会、审计委员会成员。原先在LifeCell Corp.担任董事一直到2008年的收购；担任EKR Therapeutics的董事直到2012年的收购；担任NuPathe Inc.董事直到2014年2月的收购；担任Civitas Therapeutics的董事直到2014年11月的收购。目前还在Bryn Mawr Hospital和Westtown School理事会任职。持有Colgate大学的学士学位，以及Pennsylvania大学Wharton学院的工商管理硕士学位。
Robert P. Roche has been a member of our Board of Directors since June 2014. Mr. Roche is the founding member of Robert Roche Associates, LLC, a consulting firm providing guidance to the pharmaceutical and healthcare industries. Mr. Roche created this firm upon his retirement from Cephalon, Inc., a biopharmaceutical company, in February 2010. Mr. Roche joined Cephalon in January 1995 as the Vice President of Sales and Marketing and was named Executive Vice President, Worldwide Pharmaceutical Operations of Cephalon in 2005. Before joining Cephalon, Mr. Roche served as Director and Vice President, Worldwide Strategic Product Development, for SmithKline Beecham’s central nervous system and gastrointestinal products business. Mr. Roche also was Managing Director of SmithKline’s pharmaceutical operations in the Philippines. Prior to that, he held senior marketing positions in Canada and Spain and had product planning responsibilities for SmithKline in Latin America. Mr. Roche began his pharmaceutical career in 1982 with SmithKline as a United States pharmaceutical sales representative. Mr. Roche has served as a Director of Antares Pharma, Inc., a publicly-traded specialty pharmaceutical company, since July 2013 and is currently a member of its governance and nominating committee and audit committee. In December 2016 Mr. Roche was appointed as a Director of Egalet Corporation, a publicly-traded specialty pharmaceutical company focused on innovative treatments of pain and other conditions, and is currently a member of its compensation committee and nominating and corporate governance committee. Mr. Roche is also currently a Director of Paragon Bioservices, Inc., a privately-held contract development and manufacturing organization. He formerly served as a Director of EKR Therapeutics until its acquisition in 2012 NuPathe Inc. until its acquisition in February 2014 and Civitas Therapeutics until its acquisition in November 2014. He also serves on the boards of Bryn Mawr Hospital and Westtown School. Mr. Roche earned his B.A. from Colgate University and his M.B.A. from The Wharton School at the University of Pennsylvania. - Robert P. Roche，2014年6月起担任本董事会成员。是一家为医药和医疗行业提供指导的咨询公司- Robert Roche Associates, LLC的创始成员；于2010年2月从生物医药公司Cephalon, Inc.退休后，创立了该公司。于1995年1月加入Cephalon并担任销售和市场营销副总裁；2005年被任命为Cephalon全球医药业务执行副总裁。加入Cephalon前，曾在SmithKline Beecham的中枢神经系统和胃肠道产品业务部担任董事，副总裁，负责全球战略产品发展。还曾在Philippines的SmithKline担任医药业务总经理。此前，曾在加拿大和西班牙担任高级市场营销职位，曾在拉丁美洲SmithKline担任产品规划职位。于1982年在SmithKline担任美国医药销售代表开始他的医药职业生涯。从2013年7月起，在一家专业医药上市公司- Antares Pharma, Inc.担任董事；目前是该公司管理和提名委员会、审计委员会成员。原先在LifeCell Corp.担任董事一直到2008年的收购；担任EKR Therapeutics的董事直到2012年的收购；担任NuPathe Inc.董事直到2014年2月的收购；担任Civitas Therapeutics的董事直到2014年11月的收购。目前还在Bryn Mawr Hospital和Westtown School理事会任职。持有Colgate大学的学士学位，以及Pennsylvania大学Wharton学院的工商管理硕士学位。
- Robert P. Roche has been a member of our Board of Directors since June 2014. Mr. Roche is the founding member of Robert Roche Associates, LLC, a consulting firm providing guidance to the pharmaceutical and healthcare industries. Mr. Roche created this firm upon his retirement from Cephalon, Inc., a biopharmaceutical company, in February 2010. Mr. Roche joined Cephalon in January 1995 as the Vice President of Sales and Marketing and was named Executive Vice President, Worldwide Pharmaceutical Operations of Cephalon in 2005. Before joining Cephalon, Mr. Roche served as Director and Vice President, Worldwide Strategic Product Development, for SmithKline Beecham’s central nervous system and gastrointestinal products business. Mr. Roche also was Managing Director of SmithKline’s pharmaceutical operations in the Philippines. Prior to that, he held senior marketing positions in Canada and Spain and had product planning responsibilities for SmithKline in Latin America. Mr. Roche began his pharmaceutical career in 1982 with SmithKline as a United States pharmaceutical sales representative. Mr. Roche has served as a Director of Antares Pharma, Inc., a publicly-traded specialty pharmaceutical company, since July 2013 and is currently a member of its governance and nominating committee and audit committee. In December 2016 Mr. Roche was appointed as a Director of Egalet Corporation, a publicly-traded specialty pharmaceutical company focused on innovative treatments of pain and other conditions, and is currently a member of its compensation committee and nominating and corporate governance committee. Mr. Roche is also currently a Director of Paragon Bioservices, Inc., a privately-held contract development and manufacturing organization. He formerly served as a Director of EKR Therapeutics until its acquisition in 2012 NuPathe Inc. until its acquisition in February 2014 and Civitas Therapeutics until its acquisition in November 2014. He also serves on the boards of Bryn Mawr Hospital and Westtown School. Mr. Roche earned his B.A. from Colgate University and his M.B.A. from The Wharton School at the University of Pennsylvania.
- Craig A. Tooman
-
CraigA.Tooman自2019年以来一直担任监督董事。自2019年9月以来，图曼先生一直担任Vyome Therapeutics，Inc.的首席运营官/首席财务官。此前，他曾担任Aratana Therapeutics Inc.的总裁，首席执行官兼董事会董事，并于2019年7月领导Aratana与Elanco Animal Health的合并。他自2013年起在Aratana任职。从2012年到2014年，Tooman先生担任Avanzar Medical，Inc.的首席执行官兼财务主管，该公司专注于肿瘤学。他也于2011年创立Stockbourne LLC，并一直担任负责人。2010年至2011年，图曼先生担任Ikaria，Inc.的首席财务官兼财务高级副总裁。在此之前，他从2005年到2010年担任Enzon Pharmaceuticals Inc.财务和首席财务官执行Vice President。并在与Sigma Tau的合并中发挥了关键作用。Tooman先生是Ilex Oncology Inc.战略规划和企业传播的高级副总裁，并于2004年领导了该公司与健赞公司的整合。在此之前，他曾在Pharmacia公司及其前身公司Pharmacia&Upjohn担任职责递增的高级职位，包括投资者关系Vice President。他在芝加哥大学（University of Chicago）获得金融学工商管理硕士学位，在卡拉马祖学院（Kalamazoo College）获得经济学文学学士学位。
Craig A. Tooman has served as a supervisory director since 2019. Since September of 2019 Mr. Tooman has served as the COO/CFO of Vyome Therapeutics, Inc. Prior to this, he was the President, CEO and Board Director at Aratana Therapeutics Inc. and led the merger of Aratana with Elanco Animal Health in July of 2019. He has served at Aratana since 2013. From 2012 to 2014 Mr. Tooman served as the Chief Executive Officer and Treasurer of Avanzar Medical, Inc., a company focused on oncology. He also founded Stockbourne LLC in 2011 and remains a Principal. Mr. Tooman served as the Chief Financial Officer and Senior Vice President of Finance at Ikaria, Inc. from 2010 until 2011. Before that, he served as the Executive Vice President of Finance and Chief Financial Officer of Enzon Pharmaceuticals Inc. from 2005 until 2010. and played a key role in the merger with Sigma Tau. Mr. Tooman was the Senior Vice President of Strategic Planning and Corporate Communications of ILEX Oncology Inc., and led the integration of the company with the Genzyme Corporation in 2004. Prior to this, he served in senior positions of increasing responsibility, including Vice President of Investor Relations, at Pharmacia Corporation and its predecessor company, Pharmacia & Upjohn. He received a Master of Business Administration degree in finance from the University of Chicago and a Bachelor of Arts degree in economics from Kalamazoo College. - CraigA.Tooman自2019年以来一直担任监督董事。自2019年9月以来，图曼先生一直担任Vyome Therapeutics，Inc.的首席运营官/首席财务官。此前，他曾担任Aratana Therapeutics Inc.的总裁，首席执行官兼董事会董事，并于2019年7月领导Aratana与Elanco Animal Health的合并。他自2013年起在Aratana任职。从2012年到2014年，Tooman先生担任Avanzar Medical，Inc.的首席执行官兼财务主管，该公司专注于肿瘤学。他也于2011年创立Stockbourne LLC，并一直担任负责人。2010年至2011年，图曼先生担任Ikaria，Inc.的首席财务官兼财务高级副总裁。在此之前，他从2005年到2010年担任Enzon Pharmaceuticals Inc.财务和首席财务官执行Vice President。并在与Sigma Tau的合并中发挥了关键作用。Tooman先生是Ilex Oncology Inc.战略规划和企业传播的高级副总裁，并于2004年领导了该公司与健赞公司的整合。在此之前，他曾在Pharmacia公司及其前身公司Pharmacia&Upjohn担任职责递增的高级职位，包括投资者关系Vice President。他在芝加哥大学（University of Chicago）获得金融学工商管理硕士学位，在卡拉马祖学院（Kalamazoo College）获得经济学文学学士学位。
- Craig A. Tooman has served as a supervisory director since 2019. Since September of 2019 Mr. Tooman has served as the COO/CFO of Vyome Therapeutics, Inc. Prior to this, he was the President, CEO and Board Director at Aratana Therapeutics Inc. and led the merger of Aratana with Elanco Animal Health in July of 2019. He has served at Aratana since 2013. From 2012 to 2014 Mr. Tooman served as the Chief Executive Officer and Treasurer of Avanzar Medical, Inc., a company focused on oncology. He also founded Stockbourne LLC in 2011 and remains a Principal. Mr. Tooman served as the Chief Financial Officer and Senior Vice President of Finance at Ikaria, Inc. from 2010 until 2011. Before that, he served as the Executive Vice President of Finance and Chief Financial Officer of Enzon Pharmaceuticals Inc. from 2005 until 2010. and played a key role in the merger with Sigma Tau. Mr. Tooman was the Senior Vice President of Strategic Planning and Corporate Communications of ILEX Oncology Inc., and led the integration of the company with the Genzyme Corporation in 2004. Prior to this, he served in senior positions of increasing responsibility, including Vice President of Investor Relations, at Pharmacia Corporation and its predecessor company, Pharmacia & Upjohn. He received a Master of Business Administration degree in finance from the University of Chicago and a Bachelor of Arts degree in economics from Kalamazoo College.
- Merilee Raines
-
Merilee Raines ，她是Benchmark Electronics, Inc.的董事（2011年2月以来）。她曾担任IDEXX Laboratories公司的首席财务官（从2003年10月到2013年5月退休）。成为首席财务官之前，她曾担任IDEXX Laboratories公司的多种管理职务，包括公司财务副总裁、副总裁兼财务主管、财务董事，以及总会计师。IDEXX Laboratories公司开发、生产、分销诊断和信息技术产品和服务，涉及玩赏动物、牲畜、家禽、水质量和食品安全，以及人类的现场即时诊断。她是Aratana Therapeutics公司的董事。
Merilee Raines has been a member of the Company's Board of Directors since 2018 and is a member of the Board's Audit Committee. Since 2011 Ms. Raines has been a member of the Board of Directors of Watts Water Technologies, Inc., a publicly traded manufacturer of products and systems focused on control, conservation and quality of water. She is currently a member of that company's Nominating and Corporate Governance Committee, and she serves as Chair of its Audit Committee. Ms. Raines was appointed to the Board of Directors of TransMedics Group, Inc., a medical technology company involved in organ transplant therapy, effective January 1 2021. She also serves as a member of the Audit Committee and will become the Chair effective June 1 2021. Ms. Raines also served on the Board of Directors of Aranta Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing products for the pet companion market, from 2014 until the company was acquired by Elanco Animal Health Incorporated in July 2019. Ms. Raines is currently a member of the Board of Directors of Excelitas Technologies Corporation, a privately held global industrial technology company providing sensing and detection solutions, and is Chair of its Audit committee. Ms. Raines is a member of the Board of Directors of Dead River Company, a privately held distributor of energy products and serves on its Finance and Risk Management committees. Ms. Raines was previously a member of the Board of Directors of Affymetrix, Inc., a publicly traded provider of life sciences products and molecular diagnostic products, from January 2015 to April 2016 when Thermo Fisher Scientific, Inc. acquired Affymetrix. Ms. Raines also previously served on the board of PetVet Care Centers LLC, a privately owned operator of a network of veterinary hospitals from April 2016 to February 2018 when KKR acquired PetVet. Ms. Raines served as Chief Financial Officer of IDEXX Laboratories, Inc., a publicly traded company providing diagnostic and IT products and services primarily to the companion animal health market, from October 2003 until her retirement in May 2013. Ms. Raines is a Certified Public Accountant inactive status. She received a Bachelor's Degree in Mathematics from Bowdoin College, in 1977. In 1979 she received her MBA from the University of Chicago. - Merilee Raines ，她是Benchmark Electronics, Inc.的董事（2011年2月以来）。她曾担任IDEXX Laboratories公司的首席财务官（从2003年10月到2013年5月退休）。成为首席财务官之前，她曾担任IDEXX Laboratories公司的多种管理职务，包括公司财务副总裁、副总裁兼财务主管、财务董事，以及总会计师。IDEXX Laboratories公司开发、生产、分销诊断和信息技术产品和服务，涉及玩赏动物、牲畜、家禽、水质量和食品安全，以及人类的现场即时诊断。她是Aratana Therapeutics公司的董事。
- Merilee Raines has been a member of the Company's Board of Directors since 2018 and is a member of the Board's Audit Committee. Since 2011 Ms. Raines has been a member of the Board of Directors of Watts Water Technologies, Inc., a publicly traded manufacturer of products and systems focused on control, conservation and quality of water. She is currently a member of that company's Nominating and Corporate Governance Committee, and she serves as Chair of its Audit Committee. Ms. Raines was appointed to the Board of Directors of TransMedics Group, Inc., a medical technology company involved in organ transplant therapy, effective January 1 2021. She also serves as a member of the Audit Committee and will become the Chair effective June 1 2021. Ms. Raines also served on the Board of Directors of Aranta Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing products for the pet companion market, from 2014 until the company was acquired by Elanco Animal Health Incorporated in July 2019. Ms. Raines is currently a member of the Board of Directors of Excelitas Technologies Corporation, a privately held global industrial technology company providing sensing and detection solutions, and is Chair of its Audit committee. Ms. Raines is a member of the Board of Directors of Dead River Company, a privately held distributor of energy products and serves on its Finance and Risk Management committees. Ms. Raines was previously a member of the Board of Directors of Affymetrix, Inc., a publicly traded provider of life sciences products and molecular diagnostic products, from January 2015 to April 2016 when Thermo Fisher Scientific, Inc. acquired Affymetrix. Ms. Raines also previously served on the board of PetVet Care Centers LLC, a privately owned operator of a network of veterinary hospitals from April 2016 to February 2018 when KKR acquired PetVet. Ms. Raines served as Chief Financial Officer of IDEXX Laboratories, Inc., a publicly traded company providing diagnostic and IT products and services primarily to the companion animal health market, from October 2003 until her retirement in May 2013. Ms. Raines is a Certified Public Accountant inactive status. She received a Bachelor's Degree in Mathematics from Bowdoin College, in 1977. In 1979 she received her MBA from the University of Chicago.
- Craig A. Barbarosh
-
Craig A. Barbarosh，2010年11月起担任本公司董事。2012年6月以来，他是律师事务所Katten Muchin Rosenman “Katten”的合伙人；目前是全国知名的建筑行业相关的专家。他现任Katten的执行委员会成员、董事、管理团队成员。1999年起，他担任律师事务所Pillsbury Winthrop Shaw Pittman LLP （“Pillsbury”）的合伙人，直到加入Katten。在Katten担任合伙人期间，他还担任过一些领导职务，包括：董事、战略委员会主席、全国破产与重组业务的共同领导人、Orange County办事处的管理合伙人。他目前还是Quality Systems的董事、提名与治理委员会主席、交易与薪酬委员会成员，这是医疗信息开发、销售公司。1992年，他以优异的成绩获得University of the Pacific, McGeorge School of Law的法律博士学位；1989年，在University of California at Santa Barbara获得商业经济学士学位。2007年，和2010年，他在Harvard Business School分别完成了私募股权与风险资本，和商业评估战略财务分析的高级经理教育课程，并获得相关证书。
Craig A. Barbarosh,has been a director of the company since October 2019 and has served as the chairperson of the Company's Board of Directors since October 2020. Mr. Barbarosh having served on several public companies' Boards of Directors, including current board positions with Sabra Health Care REIT, Inc. (where he is Chair of the Audit Committee) since November 2010, Evolent Health, Inc. (where he is Co-Chair of the Strategy Committee) since December 2020 and Mountain Express Oil, Inc. (where he is a Special Committee member) since March 2023. He also previously served on the board of directors of NextGen Healthcare, Inc. (where he was Chair of the Compensation Committee) from January 2015 to November 2023. He has been recognized for successes in business strategy, operational excellence, corporate governance and capital markets transactions. From June 2012 to January 2023 Mr. Barbarosh was a partner at the international law firm of Katten Muchin Rosenman LLP and previously from 1999 to June 2012 was a partner of the international law firm of Pillsbury Winthrop Shaw Pittman LLP. Mr. Barbarosh received a Juris Doctorate from the University of the Pacific, McGeorge School of Law in 1992, with distinction, and a Bachelor of Arts in Business Economics from the University of California at Santa Barbara in 1989. Mr. Barbarosh received certificates from Harvard Business School for completing executive education courses on Private Equity and Venture Capital (2007), Financial Analysis for Business Evaluation (2010) and Effective Corporate Boards (2015), from the University of Pennsylvania Wharton School program on Corporate Valuation (2019), and from the Carnegie Mellon University program in Cybersecurity Oversight (2019). Mr. Barbarosh is also a frequent speaker and author on restructuring and governance issues and has published several articles addressing business, governance, and legal topics. - Craig A. Barbarosh，2010年11月起担任本公司董事。2012年6月以来，他是律师事务所Katten Muchin Rosenman “Katten”的合伙人；目前是全国知名的建筑行业相关的专家。他现任Katten的执行委员会成员、董事、管理团队成员。1999年起，他担任律师事务所Pillsbury Winthrop Shaw Pittman LLP （“Pillsbury”）的合伙人，直到加入Katten。在Katten担任合伙人期间，他还担任过一些领导职务，包括：董事、战略委员会主席、全国破产与重组业务的共同领导人、Orange County办事处的管理合伙人。他目前还是Quality Systems的董事、提名与治理委员会主席、交易与薪酬委员会成员，这是医疗信息开发、销售公司。1992年，他以优异的成绩获得University of the Pacific, McGeorge School of Law的法律博士学位；1989年，在University of California at Santa Barbara获得商业经济学士学位。2007年，和2010年，他在Harvard Business School分别完成了私募股权与风险资本，和商业评估战略财务分析的高级经理教育课程，并获得相关证书。
- Craig A. Barbarosh,has been a director of the company since October 2019 and has served as the chairperson of the Company's Board of Directors since October 2020. Mr. Barbarosh having served on several public companies' Boards of Directors, including current board positions with Sabra Health Care REIT, Inc. (where he is Chair of the Audit Committee) since November 2010, Evolent Health, Inc. (where he is Co-Chair of the Strategy Committee) since December 2020 and Mountain Express Oil, Inc. (where he is a Special Committee member) since March 2023. He also previously served on the board of directors of NextGen Healthcare, Inc. (where he was Chair of the Compensation Committee) from January 2015 to November 2023. He has been recognized for successes in business strategy, operational excellence, corporate governance and capital markets transactions. From June 2012 to January 2023 Mr. Barbarosh was a partner at the international law firm of Katten Muchin Rosenman LLP and previously from 1999 to June 2012 was a partner of the international law firm of Pillsbury Winthrop Shaw Pittman LLP. Mr. Barbarosh received a Juris Doctorate from the University of the Pacific, McGeorge School of Law in 1992, with distinction, and a Bachelor of Arts in Business Economics from the University of California at Santa Barbara in 1989. Mr. Barbarosh received certificates from Harvard Business School for completing executive education courses on Private Equity and Venture Capital (2007), Financial Analysis for Business Evaluation (2010) and Effective Corporate Boards (2015), from the University of Pennsylvania Wharton School program on Corporate Valuation (2019), and from the Carnegie Mellon University program in Cybersecurity Oversight (2019). Mr. Barbarosh is also a frequent speaker and author on restructuring and governance issues and has published several articles addressing business, governance, and legal topics.
- Irvine O. Hockaday, Jr.
-
Irvine O. Hockaday, Jr.，Hallmark Cards, Inc.的前总裁和首席执行官。他于2001年12月退休。在1983年加入Hallmark之前，他是Kansas City Southern Industries, Inc.的总裁和首席执行官。1978年至2002年1月，Hockaday先生是Hallmark的董事。他目前是Aratana Therapeutics, Inc.的董事。此外，在过去的5年间，他担任了Crown Media Holdings, Inc., Ford Motor Company，和Sprint Nextel Corporation的董事。 Hockaday先生是首席董事和审计委员会主席。
Irvine O. Hockaday, Jr. is the former President and Chief Executive Officer of Hallmark Cards, Inc. Prior to joining Hallmark in 1983 he was President and Chief Executive Officer of Kansas City Southern Industries, Inc. Mr. Hockaday retired from Hallmark in December 2001 and he was a member of the Hallmark Board of Directors from 1978 until January 2002. Within the past five years, he served as a member of the Board of Directors of Aratana Therapeutics, Inc. - Irvine O. Hockaday, Jr.，Hallmark Cards, Inc.的前总裁和首席执行官。他于2001年12月退休。在1983年加入Hallmark之前，他是Kansas City Southern Industries, Inc.的总裁和首席执行官。1978年至2002年1月，Hockaday先生是Hallmark的董事。他目前是Aratana Therapeutics, Inc.的董事。此外，在过去的5年间，他担任了Crown Media Holdings, Inc., Ford Motor Company，和Sprint Nextel Corporation的董事。 Hockaday先生是首席董事和审计委员会主席。
- Irvine O. Hockaday, Jr. is the former President and Chief Executive Officer of Hallmark Cards, Inc. Prior to joining Hallmark in 1983 he was President and Chief Executive Officer of Kansas City Southern Industries, Inc. Mr. Hockaday retired from Hallmark in December 2001 and he was a member of the Hallmark Board of Directors from 1978 until January 2002. Within the past five years, he served as a member of the Board of Directors of Aratana Therapeutics, Inc.
- Lowell W. Robinson
-
Lowell W. Robinson，他曾担任MIVA公司（在线广告网络公司）的首席财务官兼首席运营官（从2007年到2009年）。他于2006年加入MIVA公司，作为首席财务官和首席行政官。他此前曾担任LWR Advisors公司的总裁（从2002年到2006年），以及HotJobs.com的首席财务官兼首席行政官（从2000年到2002年）。他此前曾担任Advo公司、Citigroup公司、Kraft Foods公司的高级财务职务。他也曾任职于The Jones Group的董事会（从2005年到2014年）、Local.com Corporation的董事会（从2011年到2012年）、the University of Wisconsin School of Business的咨询委员会（从2006年到2010年）、International Wire Group公司的董事会（从2003年到2009年）、Independent Wireless One公司、Diversified Investment Advisors公司、Edison Schools公司的董事会。他是美国史密森尼学会（Smithsonian Institution）图书馆咨询委员会成员，以及the Metropolitan Opera Guild的董事会成员。2009年以来，他主要任职the Jones Group公司的董事会、Local.com Corporation的董事会、the University of Wisconsin School of Business的咨询委员会。
Lowell W. Robinson,is not an "interested person" of the Company as defined in the 1940 Act. Mr. Robinson is an experienced executive with over thirty years of senior global strategic, financial, M&A, operational, turnaround and governance experience. From 2007 through 2009, Mr. Robinson served as the Chief Financial Officer and Chief Operating Officer of MIVA, Inc. (formerly NASDAQ:MIVA), an online advertising network, after initially joining the company in 2006 as its Chief Financial Officer and Chief Administrative Officer. Previously, from 2000 to 2002, he served as the Chief Financial Officer and Chief Administrative Officer at HotJobs.com Ltd. (formerly NASDAQ:HOTJ), an online recruiting and job search engine that was sold to Yahoo! Inc. Mr. Robinson was the Chief Financial Officer and Chief Administrative Officer at PRT Group Inc. (formerly NASDAQ:PRTG), a software and IT services company that he helped take public, from 1997 through 1999. Mr. Robinson also previously held senior financial positions at Advo, Inc. (formerly NYSE:AD), a leading direct-mail and marketing services company, Citigroup Inc. (NYSE:C), Uncle Bens Inc., a subsidiary of Mars, Incorporated, and Kraft Foods Inc. (formerly NYSE:KFT). Mr. Robinson served on the Board of Directors of Barnes and Noble Education Inc. (NYSE:BNED) from 2020 to 2022, where he chaired the Audit Committee and was on the Compensation Committee. He previously served as a director of each of Starboard Value Acquisition Corporation (until its merger with Cyxtera Technologies Inc. (NASDAQ:CYXT) in July 2021), Aratana Therapeutics, Inc. (NASDAQ: PETX), a commercial-stage biopharma company focused on pet products (May 2018 to July 2019) until its sale to Elanco Animal Health, ShopHQ, a digital omnichannel home shopping network (March 2014 to June 2018), Higher One Holdings, Inc. (formerly NYSE:ONE), a financial technology company focused on providing cost-saving solutions (June 2014 to August 2016), The Jones Group, Inc. (formerly NYSE:JNY), an American designer, marketer and wholesaler of branded clothing, shoes and accessories (2005 to April 2014), Independent Wireless One Corp., Diversified Investment Advisors Inc. and Edison Schools Inc. Since September 2018, Mr. Robinson serves on the executive committee and Board of Directors of The New York Academy of Science, a not-for-profit organization dedicated to driving innovative solutions to society's challenges by advancing scientific research, education and policy. He previously was on the non-profit boards of The Council for Economic Education, The Metropolitan Opera Guild, the Smithsonian Libraries and the University of Wisconsin School of Business, where he currently is on the Advisory Board for its Department of Economics. - Lowell W. Robinson，他曾担任MIVA公司（在线广告网络公司）的首席财务官兼首席运营官（从2007年到2009年）。他于2006年加入MIVA公司，作为首席财务官和首席行政官。他此前曾担任LWR Advisors公司的总裁（从2002年到2006年），以及HotJobs.com的首席财务官兼首席行政官（从2000年到2002年）。他此前曾担任Advo公司、Citigroup公司、Kraft Foods公司的高级财务职务。他也曾任职于The Jones Group的董事会（从2005年到2014年）、Local.com Corporation的董事会（从2011年到2012年）、the University of Wisconsin School of Business的咨询委员会（从2006年到2010年）、International Wire Group公司的董事会（从2003年到2009年）、Independent Wireless One公司、Diversified Investment Advisors公司、Edison Schools公司的董事会。他是美国史密森尼学会（Smithsonian Institution）图书馆咨询委员会成员，以及the Metropolitan Opera Guild的董事会成员。2009年以来，他主要任职the Jones Group公司的董事会、Local.com Corporation的董事会、the University of Wisconsin School of Business的咨询委员会。
- Lowell W. Robinson,is not an "interested person" of the Company as defined in the 1940 Act. Mr. Robinson is an experienced executive with over thirty years of senior global strategic, financial, M&A, operational, turnaround and governance experience. From 2007 through 2009, Mr. Robinson served as the Chief Financial Officer and Chief Operating Officer of MIVA, Inc. (formerly NASDAQ:MIVA), an online advertising network, after initially joining the company in 2006 as its Chief Financial Officer and Chief Administrative Officer. Previously, from 2000 to 2002, he served as the Chief Financial Officer and Chief Administrative Officer at HotJobs.com Ltd. (formerly NASDAQ:HOTJ), an online recruiting and job search engine that was sold to Yahoo! Inc. Mr. Robinson was the Chief Financial Officer and Chief Administrative Officer at PRT Group Inc. (formerly NASDAQ:PRTG), a software and IT services company that he helped take public, from 1997 through 1999. Mr. Robinson also previously held senior financial positions at Advo, Inc. (formerly NYSE:AD), a leading direct-mail and marketing services company, Citigroup Inc. (NYSE:C), Uncle Bens Inc., a subsidiary of Mars, Incorporated, and Kraft Foods Inc. (formerly NYSE:KFT). Mr. Robinson served on the Board of Directors of Barnes and Noble Education Inc. (NYSE:BNED) from 2020 to 2022, where he chaired the Audit Committee and was on the Compensation Committee. He previously served as a director of each of Starboard Value Acquisition Corporation (until its merger with Cyxtera Technologies Inc. (NASDAQ:CYXT) in July 2021), Aratana Therapeutics, Inc. (NASDAQ: PETX), a commercial-stage biopharma company focused on pet products (May 2018 to July 2019) until its sale to Elanco Animal Health, ShopHQ, a digital omnichannel home shopping network (March 2014 to June 2018), Higher One Holdings, Inc. (formerly NYSE:ONE), a financial technology company focused on providing cost-saving solutions (June 2014 to August 2016), The Jones Group, Inc. (formerly NYSE:JNY), an American designer, marketer and wholesaler of branded clothing, shoes and accessories (2005 to April 2014), Independent Wireless One Corp., Diversified Investment Advisors Inc. and Edison Schools Inc. Since September 2018, Mr. Robinson serves on the executive committee and Board of Directors of The New York Academy of Science, a not-for-profit organization dedicated to driving innovative solutions to society's challenges by advancing scientific research, education and policy. He previously was on the non-profit boards of The Council for Economic Education, The Metropolitan Opera Guild, the Smithsonian Libraries and the University of Wisconsin School of Business, where he currently is on the Advisory Board for its Department of Economics.
- John Vander Vort
-
John Vander Vort, Esq。自2012年9月起，出任公司董事会成员。Vander先生目前是Charlesbank Capital Partners的常务董事和首席运营官，这是一家私人直接投资公司。Vander先生于2013年9月离开MPM Asset Management LLC后，加入Charlesbank公司的资产管理公司，前者是一家风险资本公司，在那里，他于2005年5月起担任董事总经理、首席运营官以及首席合规官；2008年2月到2010年11月，他曾担任MPM收购的一个上市的壳牌公司的董事。加入MPM资产管理公司之前，从2003到2005年，他担任DuPont Capital Management投资组合的经理。在这之前，他是BlueStream Ventures的一个合伙人兼创始人之一，这是一家风险资本公司。在此之前，他是一个Dain Rauscher Wessels 公司（现在改为加拿大皇家银行）的管理董事。在那里，他是西海岸的网络和通信的投资的负责人，并担任顾问，领导风险投资支持的技术公司。Vander先生在Cooley Godward的旧金山办事处开始了他的职业生涯，作为风险资本公司和风险投资支持的公司的代表。Vander先生获得了Amherst College的学士学位和芝加哥大学法学院（The University of Chicago Law School）博士学位。
John Vander Vort has been a member of our Board of Directors since September 2012. Mr. Vander Vort is currently a Managing Director at Pilot House Associates, LLC, a family investment office based in Boston which he joined in September 2014. Prior to this role, Mr. Vander Vort was a Managing Director and the Chief Operating Officer of Charlesbank Capital Partners, a private equity firm. Mr. Vander Vort joined Charlesbank in September 2013 from MPM Asset Management LLC, a venture capital firm, where he served as a Managing Director, the Chief Operating Officer and the Chief Compliance Officer since May 2005 and he served on the Board of Directors of MPM Acquisition Corp., a public shell company, from February 2008 to November 2010. Prior to joining MPM Asset Management, from May 2003 until May 2005 he worked as Portfolio Manager for DuPont Capital Management. Prior to that, he was a General Partner and co-founder of BlueStream Ventures, a venture capital firm. Previously, he was a Managing Director at Dain Rauscher Wessels now the Royal Bank of Canada, where he was the head of the West Coast networking and communications investment banking group and served as an advisor to leading venture-backed technology companies. Mr. Vander Vort began his career as a corporate transaction attorney in the San Francisco office of Cooley Godward, where he represented venture capital firms and venture-backed companies. Mr. Vander Vort earned his B.A. from Amherst College and his J.D. from The University of Chicago Law School. - John Vander Vort, Esq。自2012年9月起，出任公司董事会成员。Vander先生目前是Charlesbank Capital Partners的常务董事和首席运营官，这是一家私人直接投资公司。Vander先生于2013年9月离开MPM Asset Management LLC后，加入Charlesbank公司的资产管理公司，前者是一家风险资本公司，在那里，他于2005年5月起担任董事总经理、首席运营官以及首席合规官；2008年2月到2010年11月，他曾担任MPM收购的一个上市的壳牌公司的董事。加入MPM资产管理公司之前，从2003到2005年，他担任DuPont Capital Management投资组合的经理。在这之前，他是BlueStream Ventures的一个合伙人兼创始人之一，这是一家风险资本公司。在此之前，他是一个Dain Rauscher Wessels 公司（现在改为加拿大皇家银行）的管理董事。在那里，他是西海岸的网络和通信的投资的负责人，并担任顾问，领导风险投资支持的技术公司。Vander先生在Cooley Godward的旧金山办事处开始了他的职业生涯，作为风险资本公司和风险投资支持的公司的代表。Vander先生获得了Amherst College的学士学位和芝加哥大学法学院（The University of Chicago Law School）博士学位。
- John Vander Vort has been a member of our Board of Directors since September 2012. Mr. Vander Vort is currently a Managing Director at Pilot House Associates, LLC, a family investment office based in Boston which he joined in September 2014. Prior to this role, Mr. Vander Vort was a Managing Director and the Chief Operating Officer of Charlesbank Capital Partners, a private equity firm. Mr. Vander Vort joined Charlesbank in September 2013 from MPM Asset Management LLC, a venture capital firm, where he served as a Managing Director, the Chief Operating Officer and the Chief Compliance Officer since May 2005 and he served on the Board of Directors of MPM Acquisition Corp., a public shell company, from February 2008 to November 2010. Prior to joining MPM Asset Management, from May 2003 until May 2005 he worked as Portfolio Manager for DuPont Capital Management. Prior to that, he was a General Partner and co-founder of BlueStream Ventures, a venture capital firm. Previously, he was a Managing Director at Dain Rauscher Wessels now the Royal Bank of Canada, where he was the head of the West Coast networking and communications investment banking group and served as an advisor to leading venture-backed technology companies. Mr. Vander Vort began his career as a corporate transaction attorney in the San Francisco office of Cooley Godward, where he represented venture capital firms and venture-backed companies. Mr. Vander Vort earned his B.A. from Amherst College and his J.D. from The University of Chicago Law School.
- Laura Brege
-
Laura Brege，2012年7月她获委任为董事，现任Nodality的总裁兼首席执行官，这是一家私人持有的生物技术公司，专注于提高癌症和自身免疫性疾病的治疗学的发展和临床应用。她担任阿卡迪亚制药公司、Pacira制药公司和Aratana Therapeutics公司的董事会成员，并是BayBio的董事会成员，这是北加州的一家服务于生命科学产业的独立的、非营利性的行业协会。她拥有超过20年的制药、生物技术和风险投资行业的行政管理经验。在加入Nodality之前，她在Onyx制药公司担任多个高级职位，包括执行副总裁兼首席运营官。而在Onyx，她带领多项功能，其中包括商业化、战略规划、企业发展以及医疗、科研和政府事务。在Onyx之前，她是红岩资本管理的一位普通合伙，这是一家风险投资公司，专注于科技公司的早期融资。此前她是COR治疗的高级副总裁兼首席财务官，有助于通过商业发射成功的心血管产品从早期研发公司建立公司。在她的职业生涯早期，她曾担任 Flextronics公司的首席财务官和库珀公司的财务总监。她获得了俄亥俄大学荣誉教学学院经济学和政治学的本科学位；和芝加哥大学工商管理硕士学位。
Laura Brege,has served as a director of the Company since May 2008. Since April 2017, Ms. Brege has served as a Senior Advisor to BridgeBio Pharma, Inc. From September 2015 to December 2017, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a consulting firm providing integrated business solutions to life sciences companies. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including Executive Vice President and Chief Operating Officer. While at Onyx, Ms. Brege led multiple functions, including commercialization, strategic planning, corporate development and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Previously, Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc., where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, Ms. Brege served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of Edgewise Therapeutics, Inc., HLS Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Pacira BioSciences, Inc. and T-knife Therapeutics, Inc. During the past five years, Ms. Brege has served on the boards of directors of Aratana Therapeutics, Inc., California Life Sciences Association, Dynavax Technologies Corporation and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. - Laura Brege，2012年7月她获委任为董事，现任Nodality的总裁兼首席执行官，这是一家私人持有的生物技术公司，专注于提高癌症和自身免疫性疾病的治疗学的发展和临床应用。她担任阿卡迪亚制药公司、Pacira制药公司和Aratana Therapeutics公司的董事会成员，并是BayBio的董事会成员，这是北加州的一家服务于生命科学产业的独立的、非营利性的行业协会。她拥有超过20年的制药、生物技术和风险投资行业的行政管理经验。在加入Nodality之前，她在Onyx制药公司担任多个高级职位，包括执行副总裁兼首席运营官。而在Onyx，她带领多项功能，其中包括商业化、战略规划、企业发展以及医疗、科研和政府事务。在Onyx之前，她是红岩资本管理的一位普通合伙，这是一家风险投资公司，专注于科技公司的早期融资。此前她是COR治疗的高级副总裁兼首席财务官，有助于通过商业发射成功的心血管产品从早期研发公司建立公司。在她的职业生涯早期，她曾担任 Flextronics公司的首席财务官和库珀公司的财务总监。她获得了俄亥俄大学荣誉教学学院经济学和政治学的本科学位；和芝加哥大学工商管理硕士学位。
- Laura Brege,has served as a director of the Company since May 2008. Since April 2017, Ms. Brege has served as a Senior Advisor to BridgeBio Pharma, Inc. From September 2015 to December 2017, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a consulting firm providing integrated business solutions to life sciences companies. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including Executive Vice President and Chief Operating Officer. While at Onyx, Ms. Brege led multiple functions, including commercialization, strategic planning, corporate development and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Previously, Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc., where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, Ms. Brege served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of Edgewise Therapeutics, Inc., HLS Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Pacira BioSciences, Inc. and T-knife Therapeutics, Inc. During the past five years, Ms. Brege has served on the boards of directors of Aratana Therapeutics, Inc., California Life Sciences Association, Dynavax Technologies Corporation and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.
- Wendy L. Yarno
-
Wendy L. Yarno，她从2013年起担任Inovio Pharmaceuticals, Inc.董事。她目前是薪酬委员会（Compensation Committee）主席及提名与公司管理委员会（Nominating and Corporate Governance Committee）成员。她在Merck & Co., Inc.商业与人力资源职位工作了26年，位至首席营销官，于2008年退休。那时，她领导一个全球性组织，主管各方对多达20个治疗领域的医药品商业化的支持。在此之前，她担任过心血管新陈代谢美国业务总经理，负责Merck最大的治疗领域的损益以及人力资源高级副总裁。从Merck退休后，从2012年9月至2011年9月，她在生物科技研究公司HemoShear LLC担任兼职首席营销官，HemoShear LLC是人类细胞替代系统领导开发者，用以探索评估新药物成分。从2011年9月起，她一直是生命科学产业的一名独立顾问。从2002年起，她担任财富500强医疗设备公司St. Jude Medical, Inc.的董事，从2013年10月起，担任Aratana Therapeutics的董事，Aratana Therapeutics是研发宠物药物的生物制药公司。她还在许多私有保健公司担任过董事和咨询董事会成员。她从波特兰州立大学（Portland State University）获得商业管理学士学位，并从天普大学（Temple University）获得工商管理学硕士学位。
Wendy L. Yarno,retired in 2008 from Merck & Company, Inc. following a 26-year career in commercial and human resource positions of increasing seniority, most recently as Chief Marketing Officer before she retired. Ms. Yarno also spent part of her career at Johnson & Johnson, Inc. in commercial positions. Ms. Yarno currently serves on the boards of directors of the publicly traded companies Ideaya Biosciences, Inc. and Tarsus Pharmaceuticals. Within the last five years, Ms. Yarno served on the board of directors of Global Blood Therapeutics, Inc., MyoKardia, Inc., Alder Biopharmaceuticals, Inc. and Aratana Therapeutics, Inc. Ms. Yarno holds a B.S. in Business Administration from Portland State University and an M.B.A. from Temple University. - Wendy L. Yarno，她从2013年起担任Inovio Pharmaceuticals, Inc.董事。她目前是薪酬委员会（Compensation Committee）主席及提名与公司管理委员会（Nominating and Corporate Governance Committee）成员。她在Merck & Co., Inc.商业与人力资源职位工作了26年，位至首席营销官，于2008年退休。那时，她领导一个全球性组织，主管各方对多达20个治疗领域的医药品商业化的支持。在此之前，她担任过心血管新陈代谢美国业务总经理，负责Merck最大的治疗领域的损益以及人力资源高级副总裁。从Merck退休后，从2012年9月至2011年9月，她在生物科技研究公司HemoShear LLC担任兼职首席营销官，HemoShear LLC是人类细胞替代系统领导开发者，用以探索评估新药物成分。从2011年9月起，她一直是生命科学产业的一名独立顾问。从2002年起，她担任财富500强医疗设备公司St. Jude Medical, Inc.的董事，从2013年10月起，担任Aratana Therapeutics的董事，Aratana Therapeutics是研发宠物药物的生物制药公司。她还在许多私有保健公司担任过董事和咨询董事会成员。她从波特兰州立大学（Portland State University）获得商业管理学士学位，并从天普大学（Temple University）获得工商管理学硕士学位。
- Wendy L. Yarno,retired in 2008 from Merck & Company, Inc. following a 26-year career in commercial and human resource positions of increasing seniority, most recently as Chief Marketing Officer before she retired. Ms. Yarno also spent part of her career at Johnson & Johnson, Inc. in commercial positions. Ms. Yarno currently serves on the boards of directors of the publicly traded companies Ideaya Biosciences, Inc. and Tarsus Pharmaceuticals. Within the last five years, Ms. Yarno served on the board of directors of Global Blood Therapeutics, Inc., MyoKardia, Inc., Alder Biopharmaceuticals, Inc. and Aratana Therapeutics, Inc. Ms. Yarno holds a B.S. in Business Administration from Portland State University and an M.B.A. from Temple University.
- David L. Brinkley
-
David L. Brinkley 自2014年3月份以来，担任公司董事会成员。从2000到2013年，Brinkley先生为Theravance公司工作，这是一家公开上市的生物制药公司。从2008年11月到2013年7月，担任其业务开发主管。从2000年9月到2007年12月，Brinkley先生曾担任Theravance公司商业发展部门的高级副总裁，完了以后他辞职开始了咨询业务。从1996到2000年，他担任在辉瑞伟哥的全球团队的负责人，领导伟哥的全球发布和营销团队。1995年，在辉瑞收购SmithKline Beecham's Animal Health operations时， Brinkley先生加入辉瑞公司，并担任新产品规划部门董事（领导伟哥团队之前）。1983年到1995年，Brinkley先生担任过SmithKline Animal Health公司的各种管理职务。从2013年7月卡爱是，Brinkley先生一直担任Ziarco Pharma Ltd的董事会。他持有约翰霍普金斯大学国际先进专业研究学院文学学士学位，以及以优异成绩获得肯特州立大学（Kent State University）国际关系学士学位。
David L. Brinkley has been a member of our Board of Directors since March 2014. Mr. Brinkley worked for Theravance, Inc., a publicly-traded biopharmaceutical company, from 2000 to 2013 most recently as the Head of Business Development from November 2008 to July 2013. Mr. Brinkley had previously served as Senior Vice President, Commercial Development at Theravance from September 2000 through December 2007 when he left to start a consulting practice. From 1996 to 2000 he served as Worldwide Team Leader for Viagra at Pfizer Inc., leading the team that had full responsibility for the global launch and marketing of Viagra. Mr. Brinkley joined Pfizer in 1995 through its acquisition of SmithKline Beecham’s Animal Health operations and was Director of New Product Planning before leading the Viagra launch team. Mr. Brinkley held various management positions with SmithKline Animal Health from 1983 to 1995. Mr. Brinkley previously served on the Board of Directors of Ziarco Pharma Ltd., a privately-held pharmaceutical company. Mr. Brinkley holds an M.A. with honors in International Economics from the School of Advanced International Studies of the Johns Hopkins University and a B.A. in International Relations from Kent State University, where he graduated with University Honors. - David L. Brinkley 自2014年3月份以来，担任公司董事会成员。从2000到2013年，Brinkley先生为Theravance公司工作，这是一家公开上市的生物制药公司。从2008年11月到2013年7月，担任其业务开发主管。从2000年9月到2007年12月，Brinkley先生曾担任Theravance公司商业发展部门的高级副总裁，完了以后他辞职开始了咨询业务。从1996到2000年，他担任在辉瑞伟哥的全球团队的负责人，领导伟哥的全球发布和营销团队。1995年，在辉瑞收购SmithKline Beecham's Animal Health operations时， Brinkley先生加入辉瑞公司，并担任新产品规划部门董事（领导伟哥团队之前）。1983年到1995年，Brinkley先生担任过SmithKline Animal Health公司的各种管理职务。从2013年7月卡爱是，Brinkley先生一直担任Ziarco Pharma Ltd的董事会。他持有约翰霍普金斯大学国际先进专业研究学院文学学士学位，以及以优异成绩获得肯特州立大学（Kent State University）国际关系学士学位。
- David L. Brinkley has been a member of our Board of Directors since March 2014. Mr. Brinkley worked for Theravance, Inc., a publicly-traded biopharmaceutical company, from 2000 to 2013 most recently as the Head of Business Development from November 2008 to July 2013. Mr. Brinkley had previously served as Senior Vice President, Commercial Development at Theravance from September 2000 through December 2007 when he left to start a consulting practice. From 1996 to 2000 he served as Worldwide Team Leader for Viagra at Pfizer Inc., leading the team that had full responsibility for the global launch and marketing of Viagra. Mr. Brinkley joined Pfizer in 1995 through its acquisition of SmithKline Beecham’s Animal Health operations and was Director of New Product Planning before leading the Viagra launch team. Mr. Brinkley held various management positions with SmithKline Animal Health from 1983 to 1995. Mr. Brinkley previously served on the Board of Directors of Ziarco Pharma Ltd., a privately-held pharmaceutical company. Mr. Brinkley holds an M.A. with honors in International Economics from the School of Advanced International Studies of the Johns Hopkins University and a B.A. in International Relations from Kent State University, where he graduated with University Honors.
高管简历
中英对照 | 中文 | 英文- Craig A. Tooman
CraigA.Tooman自2019年以来一直担任监督董事。自2019年9月以来，图曼先生一直担任Vyome Therapeutics，Inc.的首席运营官/首席财务官。此前，他曾担任Aratana Therapeutics Inc.的总裁，首席执行官兼董事会董事，并于2019年7月领导Aratana与Elanco Animal Health的合并。他自2013年起在Aratana任职。从2012年到2014年，Tooman先生担任Avanzar Medical，Inc.的首席执行官兼财务主管，该公司专注于肿瘤学。他也于2011年创立Stockbourne LLC，并一直担任负责人。2010年至2011年，图曼先生担任Ikaria，Inc.的首席财务官兼财务高级副总裁。在此之前，他从2005年到2010年担任Enzon Pharmaceuticals Inc.财务和首席财务官执行Vice President。并在与Sigma Tau的合并中发挥了关键作用。Tooman先生是Ilex Oncology Inc.战略规划和企业传播的高级副总裁，并于2004年领导了该公司与健赞公司的整合。在此之前，他曾在Pharmacia公司及其前身公司Pharmacia&Upjohn担任职责递增的高级职位，包括投资者关系Vice President。他在芝加哥大学（University of Chicago）获得金融学工商管理硕士学位，在卡拉马祖学院（Kalamazoo College）获得经济学文学学士学位。
Craig A. Tooman has served as a supervisory director since 2019. Since September of 2019 Mr. Tooman has served as the COO/CFO of Vyome Therapeutics, Inc. Prior to this, he was the President, CEO and Board Director at Aratana Therapeutics Inc. and led the merger of Aratana with Elanco Animal Health in July of 2019. He has served at Aratana since 2013. From 2012 to 2014 Mr. Tooman served as the Chief Executive Officer and Treasurer of Avanzar Medical, Inc., a company focused on oncology. He also founded Stockbourne LLC in 2011 and remains a Principal. Mr. Tooman served as the Chief Financial Officer and Senior Vice President of Finance at Ikaria, Inc. from 2010 until 2011. Before that, he served as the Executive Vice President of Finance and Chief Financial Officer of Enzon Pharmaceuticals Inc. from 2005 until 2010. and played a key role in the merger with Sigma Tau. Mr. Tooman was the Senior Vice President of Strategic Planning and Corporate Communications of ILEX Oncology Inc., and led the integration of the company with the Genzyme Corporation in 2004. Prior to this, he served in senior positions of increasing responsibility, including Vice President of Investor Relations, at Pharmacia Corporation and its predecessor company, Pharmacia & Upjohn. He received a Master of Business Administration degree in finance from the University of Chicago and a Bachelor of Arts degree in economics from Kalamazoo College.- CraigA.Tooman自2019年以来一直担任监督董事。自2019年9月以来，图曼先生一直担任Vyome Therapeutics，Inc.的首席运营官/首席财务官。此前，他曾担任Aratana Therapeutics Inc.的总裁，首席执行官兼董事会董事，并于2019年7月领导Aratana与Elanco Animal Health的合并。他自2013年起在Aratana任职。从2012年到2014年，Tooman先生担任Avanzar Medical，Inc.的首席执行官兼财务主管，该公司专注于肿瘤学。他也于2011年创立Stockbourne LLC，并一直担任负责人。2010年至2011年，图曼先生担任Ikaria，Inc.的首席财务官兼财务高级副总裁。在此之前，他从2005年到2010年担任Enzon Pharmaceuticals Inc.财务和首席财务官执行Vice President。并在与Sigma Tau的合并中发挥了关键作用。Tooman先生是Ilex Oncology Inc.战略规划和企业传播的高级副总裁，并于2004年领导了该公司与健赞公司的整合。在此之前，他曾在Pharmacia公司及其前身公司Pharmacia&Upjohn担任职责递增的高级职位，包括投资者关系Vice President。他在芝加哥大学（University of Chicago）获得金融学工商管理硕士学位，在卡拉马祖学院（Kalamazoo College）获得经济学文学学士学位。
- Craig A. Tooman has served as a supervisory director since 2019. Since September of 2019 Mr. Tooman has served as the COO/CFO of Vyome Therapeutics, Inc. Prior to this, he was the President, CEO and Board Director at Aratana Therapeutics Inc. and led the merger of Aratana with Elanco Animal Health in July of 2019. He has served at Aratana since 2013. From 2012 to 2014 Mr. Tooman served as the Chief Executive Officer and Treasurer of Avanzar Medical, Inc., a company focused on oncology. He also founded Stockbourne LLC in 2011 and remains a Principal. Mr. Tooman served as the Chief Financial Officer and Senior Vice President of Finance at Ikaria, Inc. from 2010 until 2011. Before that, he served as the Executive Vice President of Finance and Chief Financial Officer of Enzon Pharmaceuticals Inc. from 2005 until 2010. and played a key role in the merger with Sigma Tau. Mr. Tooman was the Senior Vice President of Strategic Planning and Corporate Communications of ILEX Oncology Inc., and led the integration of the company with the Genzyme Corporation in 2004. Prior to this, he served in senior positions of increasing responsibility, including Vice President of Investor Relations, at Pharmacia Corporation and its predecessor company, Pharmacia & Upjohn. He received a Master of Business Administration degree in finance from the University of Chicago and a Bachelor of Arts degree in economics from Kalamazoo College.
- Rhonda L. Hellums
RhondaL.Hellums自2019年2月1日起担任我们的首席财务官兼财务主管。此外，她于2014年3月至2019年1月31日担任我们的财务Vice President，并于2013年11月至2014年3月担任公司顾问。Hellums女士此前曾于2010年1月至2014年3月担任医疗设备公司Acelity L.P.Inc.的子公司KineticConcepts，Inc.“；KCI，”；的全球财务总监。Hellums女士还从2010年8月开始担任Summit Springs LLC的负责人，这是一家提供战略业务与财务咨询服务的公司。2006年1月至2010年1月，Hellums女士是生物制药公司EnzonPharmaceuticals，Inc.的财务Vice President。在此之前，Hellums女士曾担任Genzyme Corp.的财务，战略和联盟管理总监，该公司是一家全球生物制药公司，并担任Ilex Oncology，Inc.的财务和战略规划总监。Hellums女士此前曾担任EG&G Management Services（URS Corporation的一个部门）的财务总监，并担任毕马威会计师事务所（KPMG，LLC）的财务管理顾问。她拥有德克萨斯大学圣安东尼奥分校会计和信息系统学士学位和工商管理硕士学位。
Rhonda L. Hellums has served as our Chief Financial Officer and Treasurer since February 1 2019. In addition, she served as our Vice President, Finance from March 2014 to January 31 2019 and was a consultant to the Company from November 2013 to March 2014. Ms. Hellums previously served as the Director of Global Finance of Kinetic Concepts, Inc. “KCI,” a subsidiary of Acelity L.P. Inc., a medical device company, from January 2010 until March 2014. Ms. Hellums has also served as the principal of Summit Springs LLC, a firm that provides strategic business and financial consulting services, since August 2010. From January 2006 to January 2010 Ms. Hellums was the Vice President of Finance of Enzon Pharmaceuticals, Inc., a biopharmaceutical company. Prior to that, Ms. Hellums was the Director of Finance, Strategy and Alliance Management at Genzyme Corp., a global biopharmaceutical company and Director of Finance and Strategic Planning at ILEX Oncology, Inc. Ms. Hellums previously served as Controller for EG&G Management Services, a division of URS Corporation and as a financial management consultant at KPMG, LLC. She has a B.A. in Accounting and Information Systems and M.B.A. from The University of Texas at San Antonio.- RhondaL.Hellums自2019年2月1日起担任我们的首席财务官兼财务主管。此外，她于2014年3月至2019年1月31日担任我们的财务Vice President，并于2013年11月至2014年3月担任公司顾问。Hellums女士此前曾于2010年1月至2014年3月担任医疗设备公司Acelity L.P.Inc.的子公司KineticConcepts，Inc.“；KCI，”；的全球财务总监。Hellums女士还从2010年8月开始担任Summit Springs LLC的负责人，这是一家提供战略业务与财务咨询服务的公司。2006年1月至2010年1月，Hellums女士是生物制药公司EnzonPharmaceuticals，Inc.的财务Vice President。在此之前，Hellums女士曾担任Genzyme Corp.的财务，战略和联盟管理总监，该公司是一家全球生物制药公司，并担任Ilex Oncology，Inc.的财务和战略规划总监。Hellums女士此前曾担任EG&G Management Services（URS Corporation的一个部门）的财务总监，并担任毕马威会计师事务所（KPMG，LLC）的财务管理顾问。她拥有德克萨斯大学圣安东尼奥分校会计和信息系统学士学位和工商管理硕士学位。
- Rhonda L. Hellums has served as our Chief Financial Officer and Treasurer since February 1 2019. In addition, she served as our Vice President, Finance from March 2014 to January 31 2019 and was a consultant to the Company from November 2013 to March 2014. Ms. Hellums previously served as the Director of Global Finance of Kinetic Concepts, Inc. “KCI,” a subsidiary of Acelity L.P. Inc., a medical device company, from January 2010 until March 2014. Ms. Hellums has also served as the principal of Summit Springs LLC, a firm that provides strategic business and financial consulting services, since August 2010. From January 2006 to January 2010 Ms. Hellums was the Vice President of Finance of Enzon Pharmaceuticals, Inc., a biopharmaceutical company. Prior to that, Ms. Hellums was the Director of Finance, Strategy and Alliance Management at Genzyme Corp., a global biopharmaceutical company and Director of Finance and Strategic Planning at ILEX Oncology, Inc. Ms. Hellums previously served as Controller for EG&G Management Services, a division of URS Corporation and as a financial management consultant at KPMG, LLC. She has a B.A. in Accounting and Information Systems and M.B.A. from The University of Texas at San Antonio.
- Chris Ready
Chris Ready自2018年11月1日起担任销售与市场营销Vice President。此外，他曾一直担任我们的SR。2016年11月至2018年10月31日担任营销总监。此前，Ready先生于2015年1月至2016年11月担任Elanco Animal Health的伴侣动物全球营销高级总监，并负责整个伴侣动物投资组合的战略营销和品牌管理团队。在Elanco内部，他还从2005年10月到2014年12月在Companion Animal，Beef，Dairy，猪和家禽业务单元担任各种营销角色。加入Elanco之前，Ready从1996年7月到2005年10月在Bayer Animal Health任职近10年，担任多个市场营销与销售职位。Ready先生拥有堪萨斯大学（University of Kansas）生物学学士学位。
Chris Ready has served as our Vice President of Sales and Marketing since November 1 2018. In addition, he has served as our Sr. Director of Marketing from November 2016 to October 31 2018. Previously, Mr. Ready served as Senior Director of Companion Animal Global Marketing at Elanco Animal Health from January 2015 to November 2016 and was responsible for the strategic marketing and brand management teams of the entire companion animal portfolio. Within Elanco, he also held various marketing roles in the companion animal, beef, dairy, swine and poultry business units from October 2005 to December 2014. Before Elanco, Mr. Ready spent nearly 10 years with Bayer Animal Health in various marketing and sales positions from July 1996 to October 2005. Mr. Ready holds a bachelor’s degree in biology from the University of Kansas.- Chris Ready自2018年11月1日起担任销售与市场营销Vice President。此外，他曾一直担任我们的SR。2016年11月至2018年10月31日担任营销总监。此前，Ready先生于2015年1月至2016年11月担任Elanco Animal Health的伴侣动物全球营销高级总监，并负责整个伴侣动物投资组合的战略营销和品牌管理团队。在Elanco内部，他还从2005年10月到2014年12月在Companion Animal，Beef，Dairy，猪和家禽业务单元担任各种营销角色。加入Elanco之前，Ready从1996年7月到2005年10月在Bayer Animal Health任职近10年，担任多个市场营销与销售职位。Ready先生拥有堪萨斯大学（University of Kansas）生物学学士学位。
- Chris Ready has served as our Vice President of Sales and Marketing since November 1 2018. In addition, he has served as our Sr. Director of Marketing from November 2016 to October 31 2018. Previously, Mr. Ready served as Senior Director of Companion Animal Global Marketing at Elanco Animal Health from January 2015 to November 2016 and was responsible for the strategic marketing and brand management teams of the entire companion animal portfolio. Within Elanco, he also held various marketing roles in the companion animal, beef, dairy, swine and poultry business units from October 2005 to December 2014. Before Elanco, Mr. Ready spent nearly 10 years with Bayer Animal Health in various marketing and sales positions from July 1996 to October 2005. Mr. Ready holds a bachelor’s degree in biology from the University of Kansas.
- John C. Ayres
JohnC.Ayres自2019年1月1日起担任公司发展与行政Vice President，总法律顾问兼秘书。此外，他自2013年11月起担任我们的总法律顾问和秘书。此前，Ayres先生从2010年6月到2013年10月担任安进公司公司（一家公开上市的生物技术公司）的公司和证券顾问。在加入Amgen之前，Ayres先生是Latham&Watkins LLP律师事务所芝加哥办事处的律师，在那里他专门从事上市公司代表和公司交易。Ayres先生在密苏里大学（University of Missouri）获得法学博士学位。他还持有杜鲁门州立大学（Truman State University）金融学学士学位。
John C. Ayres has served as our Vice President - Corporate Development and Administration, General Counsel and Secretary since January 1 2019. In addition, he served as our General Counsel and Secretary since November 2013. Previously, Mr. Ayres served as corporate and securities counsel for Amgen Inc., a publicly-traded biotechnology company from June 2010 through October 2013. Prior to joining Amgen, Mr. Ayres was an attorney at the law firm of Latham & Watkins LLP in its Chicago office, where he specialized in public company representation and corporate transactions. Mr. Ayres earned his Juris Doctorate degree from the University of Missouri. He also holds a B.A. degree in finance from Truman State University.- JohnC.Ayres自2019年1月1日起担任公司发展与行政Vice President，总法律顾问兼秘书。此外，他自2013年11月起担任我们的总法律顾问和秘书。此前，Ayres先生从2010年6月到2013年10月担任安进公司公司（一家公开上市的生物技术公司）的公司和证券顾问。在加入Amgen之前，Ayres先生是Latham&Watkins LLP律师事务所芝加哥办事处的律师，在那里他专门从事上市公司代表和公司交易。Ayres先生在密苏里大学（University of Missouri）获得法学博士学位。他还持有杜鲁门州立大学（Truman State University）金融学学士学位。
- John C. Ayres has served as our Vice President - Corporate Development and Administration, General Counsel and Secretary since January 1 2019. In addition, he served as our General Counsel and Secretary since November 2013. Previously, Mr. Ayres served as corporate and securities counsel for Amgen Inc., a publicly-traded biotechnology company from June 2010 through October 2013. Prior to joining Amgen, Mr. Ayres was an attorney at the law firm of Latham & Watkins LLP in its Chicago office, where he specialized in public company representation and corporate transactions. Mr. Ayres earned his Juris Doctorate degree from the University of Missouri. He also holds a B.A. degree in finance from Truman State University.
- Ernst Heinen
Ernst Heinen， 兽医学博士，Heinen博士自2014年3月起一直担任我们的首席开发官。在此之前，自2012年6月起他担任我们的药品评价和发展部门主管。从1990到2012年，Heinen博士在Bayer Animal Health担任越来越多的责任，Bayer Animal Health是Bayer AG的动物健康的分公司，在那里他最终做到了宠物研究和兽医技术服务开发部门的副总裁。Heinen目前任职于堪萨斯州立大学博士奥拉西咨询委员会（ Kansas State University Olathe Advisory Board），曾担任堪萨斯市地区发展委员会的（ Kansas City Area Development Council）董事和动物健康创新中心的董事；他还是科学文章的作家，以及许多动物保健行业的演讲人。Heinen先生拥有位于德国吉森的（比希吉森大学兽医学院兽医微生物学院）Justus-Liebig-University of Giessen Veterinary School），他还是兽医微生物学方面的认证专家。
Ernst Heinen has served as our Chief Development Officer since March 5 2014. In addition, he served as our Head of Drug Evaluation and Development from June 2012 until March 5 2014. From 1990 to 2012 Dr. Heinen held positions of increasing responsibility at Bayer Animal Health, the animal health division of Bayer AG, where he ultimately served as Vice President of Research & Development and Veterinary Technical Services, Pets. Dr. Heinen currently serves on the Kansas State University Olathe Advisory Board and previously served on the boards of the Kansas City Area Development Council and the Center for Animal Health Innovation, and he is the author of dozens of scientific articles and presentations focused on the animal health industry. Dr. Heinen received a veterinary degree and a D.V.M. in veterinary microbiology from the Justus-Liebig-University of Giessen Veterinary School in Giessen, Germany, and is a certified specialist in veterinary microbiology.- Ernst Heinen， 兽医学博士，Heinen博士自2014年3月起一直担任我们的首席开发官。在此之前，自2012年6月起他担任我们的药品评价和发展部门主管。从1990到2012年，Heinen博士在Bayer Animal Health担任越来越多的责任，Bayer Animal Health是Bayer AG的动物健康的分公司，在那里他最终做到了宠物研究和兽医技术服务开发部门的副总裁。Heinen目前任职于堪萨斯州立大学博士奥拉西咨询委员会（ Kansas State University Olathe Advisory Board），曾担任堪萨斯市地区发展委员会的（ Kansas City Area Development Council）董事和动物健康创新中心的董事；他还是科学文章的作家，以及许多动物保健行业的演讲人。Heinen先生拥有位于德国吉森的（比希吉森大学兽医学院兽医微生物学院）Justus-Liebig-University of Giessen Veterinary School），他还是兽医微生物学方面的认证专家。
- Ernst Heinen has served as our Chief Development Officer since March 5 2014. In addition, he served as our Head of Drug Evaluation and Development from June 2012 until March 5 2014. From 1990 to 2012 Dr. Heinen held positions of increasing responsibility at Bayer Animal Health, the animal health division of Bayer AG, where he ultimately served as Vice President of Research & Development and Veterinary Technical Services, Pets. Dr. Heinen currently serves on the Kansas State University Olathe Advisory Board and previously served on the boards of the Kansas City Area Development Council and the Center for Animal Health Innovation, and he is the author of dozens of scientific articles and presentations focused on the animal health industry. Dr. Heinen received a veterinary degree and a D.V.M. in veterinary microbiology from the Justus-Liebig-University of Giessen Veterinary School in Giessen, Germany, and is a certified specialist in veterinary microbiology.